home / stock / lixtw / lixtw quote
Last: | $0.0597 |
---|---|
Change Percent: | -6.03% |
Open: | $0.0633 |
Close: | $0.0597 |
High: | $0.0633 |
Low: | $0.0597 |
Volume: | 599 |
Last Trade Date Time: | 06/28/2024 03:00:00 am |
Quotes are delayed by 15 to 20 minutes.
Last | Open | Close | High | Low | Volume | Date |
---|---|---|---|---|---|---|
$0.0597 | $0.0633 | $0.0597 | $0.0633 | $0.0597 | 599 | 06-28-2024 |
$0.0597 | $0.0597 | $0.0597 | $0.0597 | $0.0597 | 496 | 06-27-2024 |
$0.0597 | $0.0799 | $0.0597 | $0.0799 | $0.0597 | 1,826 | 06-26-2024 |
$0.0402 | $0.0402 | $0.0402 | $0.0402 | $0.0402 | 805 | 06-25-2024 |
$0.07 | $0.081777 | $0.07 | $0.081777 | $0.07 | 926 | 06-21-2024 |
$0.07 | $0 | $0.07 | $0 | $0 | 122 | 06-20-2024 |
$0.07 | $0.0787 | $0.07 | $0.0787 | $0.07 | 500 | 06-19-2024 |
$0.07 | $0.0787 | $0.07 | $0.0787 | $0.07 | 500 | 06-18-2024 |
$0.07 | $0.0788 | $0.07 | $0.0788 | $0.07 | 1,761 | 06-17-2024 |
$0.0824 | $0.068 | $0.0824 | $0.094 | $0.0422 | 29,090 | 06-14-2024 |
$0.0762 | $0.069101 | $0.0762 | $0.0762 | $0.0451 | 8,285 | 06-13-2024 |
$0.069 | $0.069 | $0.069 | $0.069 | $0.069 | 2,471 | 06-12-2024 |
$0.069 | $0.0691 | $0.069 | $0.0691 | $0.069 | 1,053 | 06-11-2024 |
$0.069 | $0.072 | $0.069 | $0.08 | $0.069 | 5,672 | 06-10-2024 |
$0.0655 | $0 | $0.0655 | $0 | $0 | 44 | 06-07-2024 |
$0.0655 | $0.059 | $0.0655 | $0.0655 | $0.059 | 413 | 06-06-2024 |
$0.0698 | $0.084 | $0.0698 | $0.084 | $0.0698 | 11,256 | 06-05-2024 |
$0.075 | $0.071501 | $0.075 | $0.075 | $0.071501 | 2,312 | 06-04-2024 |
$0.084 | $0 | $0.084 | $0 | $0 | 8 | 05-29-2024 |
$0.084 | $0 | $0.084 | $0 | $0 | 38 | 05-28-2024 |
News, Short Squeeze, Breakout and More Instantly...
Lixte Biotechnology Holdings Inc. Warrants Company Name:
LIXTW Stock Symbol:
NASDAQ Market:
Clinical trial to test recent findings that show LIXTE’s lead clinical compound, LB-100, increases recognition of colon cancer cells by the immune system PASADENA, CA, June 14, 2024 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc . (“LIXTE” or the ...
Clinical trial to test recent findings that show LIXTE’s lead clinical compound, LB-100, increases recognition of colon cancer cells by the immune system PASADENA, CA, June 14, 2024 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc . (“LIXTE” or the ȁ...
LB-100 Generates Neo-Antigens in Cancer Cells that are Presented to the Immune System by Disrupting the Process of RNA Splicing PASADENA, CA, June 06, 2024 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc . (“LIXTE” or the “Company”) ( ...